Running title: P4HA2 promotes glioma by collagen-PI3K/AKT pathway Highlights P4HA2 is overexpressed and correlated with poor prognosis in glioma.
Introduction
Glioma is the most common adult malignant tumors in the central neural system, which is classified into different subtypes, with the glioblastoma multiforme (GBM) being the most abundant and malignant [1] . Despite the standard therapeutics including surgical resection, adjuvant radiotherapy and chemotherapy, the prognosis remains poorly improved [2] . Hence, great challenges still exist in the clarification of the molecular mechanism of glioma malignancy, which prompts us to identify novel molecular therapeutic target for GBM.
Recent years have witnessed increasing focus on the tumor microenvironment (TME) in the development of many solid tumors including GBM [3] . As one of the most robust features of TME, hypoxia can remodel the extracellular matrix (ECM), which may correlates with reprogramming of tumor cells and leads to tumor proliferation, invasion, epithelial-to-mesenchymal transition (EMT) and therapeutic resistance [4] . These proto-oncogenic effects of hypoxia are largely dependent on the activation and stabilization of hypoxia inducible factor (HIF), which mediates signaling transduction by transactivating a series of downstream target molecules [4] . Thus, the HIF targets deserve intense attentions for their pivotal roles in the hypoxia induced glioma malignancy.
Prolyl-4-hydroxylase subunit 2 (P4HA2) has been mentioned to be directly regulated by HIF in fibroblast and breast cancer, which can modulate the ECM in the TME [5] .
In the previous work, we have demonstrated by high throughput microarray that the transcriptional level of HIF was significantly up-regulated in glioblastoma cell lines induced by hypoxia. Moreover, the binding site for HIF1α, termed as HIF reactive element(HRE), has also been identified by means of bioinformatics analysis(Dada not shown). Given the close relationship between hypoxia and cancer, it is reasonable to expect the involvement of P4HA2 in the maligmancy of glioma. In fact, deregulation of P4HA2 has been implicated in various pathological processes like osteoarthritis [6] , hepatic fibrosis [7] , giant cell arteritis [8] , nonsyndromic high myopia [9] as well as many tumors such as hepatocellular carcinoma [7] , breast cancer [10] , papillary thyroid cancer [11] , and oral cavity squamous cell carcinoma [12] . However, little is known about its expression pattern, biological functions and the role it may play in the oncogenesis of glioma.
In this study, we demonstrate that P4HA2 is overexpressed and correlated with poor prognosis in glioma. Knockdown of P4HA2 inhibits the proliferation, migration, invasion and EMT-like phenotype of hypoxia-cultured glioma cells in vitro as well as tumor xenograft growth in vivo. Mechanistically, knockdown of P4HA2 leads to inhibition of the PI3K/AKT pathway in a collagen-dependent manner. Thus, P4HA2 may serve as a potential therapeutic target for GBM patients. The migrated cells were observed under Leica inverted microscope (Solms, Germany).
Materials and methods
Cell number was counted in eight random fields for each condition. The experiments were performed in triplicate.
Migration assay. Tumor migration was determined by wound healing assay. Cells were seeded in 6-well plates and cultured to 80-90% confluence. After serum starvation for 12 h, a wound was created by scraping the cell monolayer with a 200μl pipette tip. The cultures were washed by PBS to remove the floating cells. Then the cells were cultured in serum-free medium. Cell migration into the wound was observed at the indicated times (0 h, 36 h) in marked microscopic fields and images were captured with a DS-5M Camera System (Nikon, Tokyo, Japan). The data obtained were presented as a migration rate by dividing the distances between wound edges with ImageJ software.
Quantitative RT-PCR analysis. The procedure of qRT-PCR had been previously described [13] . The gene expression was calculated using the 2 -ΔΔ Ct method. All data represent the average of three replicates. The PCR primer sequences were listed as follows. P4HA2, forward 5'-CAAACTGGTGAAGCGGCTAAA-3', reverse 5'- Western blot. The standard protocol of western blot had been described previously [14] .
In brief, the total cell lysates were prepared in high KCl lysis buffer (10 mmol/L Tris-HCl, pH 8.0, 140 mmol/L NaCl, 300 mmol/L KCl, 1 mmol/L EDTA, 0.5% Triton X-100, and 0.5% sodium deoxycholate) with complete protease inhibitor cocktail (Roche). Immunohistochemistry (IHC) staining. Tumors were fixed with 10% formalin, followed by paraffin embedding and sectioning. The protocol has been described in the previous study [14] . The percentages of positive tumor cells scored 0 (0% to 25%), 1 (26% to 50%), 2 (51% to 75%), and 3 (76% to 100%). The staining intensities were graded as follows: 0 (negative), 1 (weak), 2 (moderate), or 3 (strong). The final scores were the arithmetic product of the percentage and staining intensity, that is, (None) =0, (Low) = 1 to 3, (Medium) = 4 to 6, (High) = 7 to 9.
Animal Studies. The procedures of animal studies had been mentioned previously [14] .
All mouse experiments were carried out in accordance with institutional guidelines and regulations of the government. All mouse experiments were also approved by the Ethical Board at the General Hospital of Jinan Military Command.
Immunofluorescence and hematoxylin and eosin (H&E) staining. The procedures of immunofluorescence and H&E staining had been previously described [14] . In brief, cells on poly-L-lysine-coated glass coverslips were fixed with 4% paraformaldehyde for 15 minutes at room temperature and permeabilized by ice-cold methanol for 10 minutes. The xenografts were fixed in 4% paraformaldehyde, embedded in optimal cutting temperature compound for freezing, and then cryosectioned (10-mm sections).
After being blocked by 15% normal donkey serum for 30 minutes, the cells were incubated at room temperature for one hour with primary antibody diluted in antibody buffer. After incubation with the Ki-67 primary antibodies (Santa Cuz, sc-56319, Dallas, TX, USA), the cells were rinsed and incubated for one hour at room temperature with Alexa Fluor-labeled secondary antibodies (Molecular Probes, Waltham, MA, USA).
The cells were washed with PBS and the cover slips were mounted with glycerine/PBS were analyzed using Pearson correlation coefficient. P values less than 0.05 were considered as significant.
Results

P4HA2 is overexpressed and correlated with poor prognosis in glioma.
To examine the role of P4HA2 in glioma, we first compared the tumor expression of P4HA2 with normal tissues at the transcriptional level. By interrogating the TCGA, we found the mean transcriptional level of P4HA2 in glioma samples was higher than that in normal tissues ( Fig. 1A, p<0 .05). We next examined the relationship between P4HA2 transcriptional level and histologic grade in human glioma. As expected, we found increased P4HA2 transcriptional level was associated with increasing histologic tumor grade in glioma, which was mostly elevated in WHO IV glioma ( Fig. 1B, p<0 .001).
Then, we took advantage of the survival data in TCGA to investigate the correlation between P4HA2 transcriptional expression and prognosis of patients. The results revealed that the overall survival of patients with higher P4HA2 transcriptional expression was notably shorter than that of patients who have lower P4HA2 expression in GBM (Fig. 1C, p<0 .001). Meanwhile, immunohistochemistry in clinical samples, showed that P4HA2 was extensively expressed in the cytoplasm and the median P4HA2 post-translational level in 58 glioma samples was significantly higher than that in 5 normal tissues. Similar to the mRNA expression, we found the expressional level of P4HA2 protein increased along with the increased pathological grade of tumors ( Fig.   1D-F) . At last, by log-rank test, the overall survival of patients with higher posttranslational P4HA2 level was found to be shorter than those expressing lower P4HA2 protein, which was consistent with the transcriptional results, implying that either mRNA or protein expression of P4HA2 was negatively associated with the prognosis (Fig. 1G, p<0 .05).
Knockdown of P4HA2 inhibits proliferation, migration and invasion of glioma cells in vitro and suppresses tumorigenesis in vivo.
To explore the role of P4HA2 in glioma malignancy, the U251 and U87MG cells were chosen for the RNA interference experiment because of their relatively high P4HA2 expression level among the four GBM cell lines ( Fig. 2A) . It can be seen that both shRNAs targeting P4HA2 mRNA were effective to inhibit the expression of P4HA2 (Fig. 2B ). Malignant proliferation was among the most distinct features of glioma (ie. GBM). In view of this, WST-1 assay was performed to determine the impact of P4HA2 on cell proliferation. After stable P4HA2 knockdown, both U251 and U87MG cells showed obviously reduced rate of proliferation compared to the control group at each time point (Fig. 2C, p<0 .05).
Notably, glioma cells transfected with sh-P4HA2-2 lentivirus had a relatively lower proliferation rate than cells with sh-P4HA2-1 transfection, thus being selected for the further experiments. To clarify the role of P4HA2 interference in cell invasion, which is another aspect of glioma malignance, Matrigel invasion assay was performed to reveal that P4HA2 knockdown significantly decreased the number of invading cells in both U251 and U87MG cells at 24 hours after serum-free culture (Fig. 2C, p<0 .001).
Moreover, wound-healing assay showed that the migration rate of cells in both glioma cell lines were markedly reduced at 36 hours (Fig. 2D, p<0 .001).
Subsequently, we tried to further verify the effect of P4HA2 on tumorigenesis in vivo,
where the ECM may play a more important role than in vitro. Through subcutaneous xenograft assay in a nude mouse model with U87MG cells, which was the mostly inhibited cell line in the in vitro experiment, we found that knockdown of P4HA2 significantly inhibited tumor growth in the observed post-implantation period (Fig. 2F-G ). What is more, tissue H&E staining showed that the tumor cells with characteristics of abnormal morphology were obviously decreased in the xenograft derived from P4HA2-knockdown cells (Fig. 2I ). Consistently, fluorescent staining of cell proliferation marker Ki67 merged with nucleus showed decreased ratio of Ki-67 immunoactivity in P4HA2-knockdown xenograft compared to the control xenograft ( Fig. 2J, K) . intensively involved in the adhesion, elongation and motility of tumor cells, and collagen deposition within tumor cells has been proved to promote tumor invasion and metastasis. As the substrate of collagen hydroxylase, are collagen contents in the glioma sample also regulated by P4HA2? First of all, we found by TCGA database the expressional profiles of a spectrum of collagens in high-P4HA2 group were increased at least 2-fold compared to low-P4HA2 group (Fig.S2 ). There were significantly positive correlation in between P4HA2 mRNA and most of those collagen genes (Fig.3B) . Next, the knockdown experiment by immunoblotting in glioma cell lines intriguingly confirmed that collagen I, III and IV, three representative collagens in the brain, are in regulation of P4HA2 not only in the content of mRNA but also protein( Fig.3C ).
Knockdown of P4HA2 inhibits the EMT
P4HA2 regulates PI3K/AKT pathway of glioma cells in a collagen dependent manner.
Previous studies have determined that PI3K/AKT signaling is among the most critical pathways in the irregular molecular networks underlying the tumoregenesis of glioma [17] . In the current study bioinformatics was utilized to show that PI3K/AKT is also among the most enriched pathways associated with P4HA2 expression [17, 18] . We proposed a hypothesis that P4HA2 is required for the activation of PI3K/AKT pathway.
Interestingly, though the mRNA levels PI3K and AKT were not influenced by P4HA2 knockdown (Fig.3B) , we found by immunoblotting that P4HA2 inhibition led to reduced protein levels of phosphorylated PI3K and AKT. To our knowledge, collagens can transduce intracellular signaling through the receptor tyrosine kinases(RTKs) on the cell membrane surface [19] . To test whether it is collagen that regulates the PI3K/AKT pathway, we utilized a P4HA2 enzyme inhibitor, DHB to suppress the deposition of collagen in glioma cells. The results were the same: both phosphorylated PI3K and AKT expressions, not the total protein expressions, were significantly reduced by inhibition of the collagen hydroxylase, implying that P4HA2 regulates PI3K/AKT signaling in a collagen-dependent manner (Fig.3D) . At this point, we were strongly inspired to find out whether PI3K/AKT activation is able to mediate the protumoregenesis effect of P4HA2. By employing an AKT agonist SC79, the inhibited proliferation, invasion and migration in the P4HA2 knockdown cell line were all shown to be notably reversed ( Fig. 4E-G) . Specially, the EMT related molecules, which have been downregulated by P4HA2 knockdown, were also found to increase after AKT activation, which confirms and extends the previous finding that EMT is tightly associated with AKT family (Fig. 4H) . Taken together, this part of results indicates the transduction of collagen-PI3K/AKT, which is under the regulation of P4HA2, is possibly the underlying mechanism for the tumor-promoting effect of P4HA2.
Discussions
In this study, we firstly investigated the expression pattern and clinical significance of P4HA2 in glioma patients. We found that P4HA2 was frequently upregulated in glioma, which was consistent with its expression in other malignancies [7, [10] [11] [12] . The inverse correlation between P4HA2 and patient survival indicated that P4HA2 may serve as a promising prognostic marker in glioma. Then, the biological functions of P4HA2 was examined. Similar with the findings in breast cancer [20] , knockdown of P4HA2 was also found to inhibit glioma proliferation, migration and invasion in vitro and tumor xenograft growth in vivo. However, the underlying molecular mechanism is elusive.
EMT, a biological process characterized by the downregulation of epithelial markers
represented by E-cadherin, and the upregulation of mesenchymal markers like vimentin, fibronectin, and several key EMT inducing factors including snail, slug and twist, is a pivotal step for cell migration and invasion in various cancer types including glioma [21, 22] . Hence, the relation between P4HA2 and EMT was examined. By bioinformatic analysis, we showed that P4HA2 expression was correlated with a series of EMT-associated factors in glioma patients. Knockdown of P4HA2 was accompanied by elevation of E-cadherin and reduction of vimentin, fibronectin, snail, slug and twist, which indicated that the EMT-like phenotype may participate in the P4HA2-mediated glioma migration and invasion. However, the mechanism for P4HA2-induced cell proliferation and EMT-like phenotype still needs to be further elucidated.
By a preliminary investigation through pathway analysis of the difference between the gene expression profiles of high-and low-P4HA2 glioma patients from TCGA database, we found that the most enriched pathway was ECM-receptor interaction, which implicated that the mechanism of P4HA2 may lie in the interaction between ECM and glioma cells. Among these pathways, the PI3K/AKT signaling pathway attracted our attentions. Multiple studies have shown that the PI3K/AKT signaling pathway is a crucial cascade for cancer proliferation, migration, invasion, metastasis and therapeutic resistance [23, 24] . Besides, PI3K/AKT signaling pathway is also a common upstream regulator of the EMT-like phenotype [25] . Hence, the PI3K/AKT signaling pathway is considered as a probable mechanism for P4HA2 in glioma. By western blot, we found the PI3K/AKT signaling pathway could be either inactivated by silencing the expression or blocking the enzyme activity of P4HA2. This may indicate that the regulation of PI3K/AKT signaling pathway by P4HA2 is in a collagen-dependent manner. Then, through rescue assay with a signal agonist SC79, we further confirmed that the PI3K/AKT signaling pathway was factually required for the oncogenic role of P4HA2. Thus, the PI3K/AKT signaling pathway is considered to account for the effects of P4HA2 on glioma proliferation, migration, invasion and EMT-like phenotype.
However, how to link collagen with PI3K/AKT signaling pathway needs further clarification.
As the major frame component of ECM, a series of collagens including types I, III, IV, VI and XVI have been mentioned to be upregulated in glioma [26] [27] [28] [29] [30] , which demonstrates a crucial role of collagen in gliomagenesis. In brain tumors, collagen has three primary functions. Apart from acting as a scaffold for cell adhesion and serving as a reservoir of matricellular molecules, collagen can act as a ligand for ECM-cell signalling transduction through interacting with binding receptors [31, 32] . Currently, three types of collagen receptors have been identified in GBM. The first is integrins, a class of transmembrane receptors, which can mediate signal transduction through formation of a large adhesion complex containing signal molecules [33] . The second is discoidin domain receptors (DDRs), a class of receptor tyrosine kinases, which can mediate glioma progression via activation of downstream signal molecules [34] . The third is Endo 180, a member of the mannose receptor family, which can mediate collagen internalization and glioma invasion [35] . Among the collagen receptors, the DDRs has been tightly associated with the PI3K/AKT signaling pathway, because of the C-terminal of DDR1 kinase domain contains the YELM binding motif for association with the p85 subunit of PI3K [36] . As previous literature has demonstrated that type I-IV collagens can all combine with DDRs [37, 38] and deposited by P4HA2 [6, 20] , we think at least the DDRs could theoretically mediate the collagen-dependent regulation of PI3K/AKT signaling pathway by P4HA2 in glioma, though it needs further confirmation. With the downregulation of collagen I, III and VI by P4HA2 silencing in glioma cells, a novel signal axis of P4HA2-collagen-PI3K/AKT pathway is proposed in contribution to glioma progression. A working model of P4HA2 was proposed whereby P4HA2 catalyzes collagen deposition, promotes the interaction between collagens and their receptors to activate the PI3K/AKT signaling pathway, which leads to glioma proliferation, migration, invasion and the EMT-like phenotype However, the activation of PI3K/AKT axis by SC79 is insufficient to rescue the inhibitory effects of P4HA2 depletion, which indicates that other mechanisms may also exist. For example, previous study has mentioned that the ECM rigidity can regulate the proliferation, mobility and EMT of glioma cells [39, 40] . Whether P4HA2 can promote glioma progression by directly enhancing ECM rigidity(changing the physical property of ECM) through depositing collagens needs further exploration. Besides, considering the focal adhesion kinase (FAK) signaling pathway is another oncogenic mechanism for glioma malignant behaviors [41] , the collagen-dependent regulation of focal adhesion by P4HA2 also merits attention. Moreover, P4HA2 may also enhance glioma stenmess and neovascularization, because the same function has been reported in P4HA1, an isoform of P4HA2, by promoting glioma stem cell-endothelial cell transdifferentiation and the collagen IV dependent formation of vascular basement membrane [42] . Besides collagen-dependent mechanism, P4HA2 has recently been reported to promote B-cell lymphoma progression via hydroxylation of Carabin [43] .
This indicates that the substrates of P4HA2 are not limited to collagens, which is beneficial for a deeper understanding of the role played by P4HA2 in cancer biology.
In conclusion, our study first demonstrates that P4HA2 is a potential oncoprotein participating in glioma pathogenesis, which may serve as a prognostic marker in glioma.
Besides, we reveal a potential P4HA2-collagen-PI3K/AKT pathway in mediating the glioma progression, which sheds light on the importance of interplay between glioma cells and their microenvironment in glioma progression. Targeting P4HA2 by developing specific enzymatic inhibitors or RNA interference may represent a potential therapeutic strategy in the treatment of GBM. 
